In 2019, According to a Report Published in the International Journal of Gynaecology & Obstetrics, Dysmenorrhea Affects More than 80% of Women of Reproductive Age and is the Most Common Gynaecological Issue Across Globe

Dysmenorrhea is a medical terminology used for menstrual cramps in which the female has extreme cramps in her lower abdomen, which can spread to the lower legs and back. Most women tend to have dysmenorrhea during puberty, typically within four to five years of the first menstrual cycle. Prostaglandins are chemicals produced in the lining of the uterus during menstruation. These prostaglandins trigger muscle contractions in the uterus, which cause discomfort and reduce blood flow and oxygen flow to the uterus.         

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-menstrual-cramps-treatment-market

Global menstrual cramp treatment market is expected to reach USD 7,568.89 million by 2028 from USD 4,183.52 million in 2020, growing at a CAGR of 7.8% in the forecast period of 2021 to 2028.   Increasing prevalence of dysmenorrhea, rising level of awareness and growing concern about dysmenorrhea among women in developed countries and companies' involvement in developing innovative medicines effectively help the growth of the menstrual cramp treatment market.            

menstrual cramp treatment market

Rising prevalence of dysmenorrhea is leading to increased adoption of menstrual cramp treatment across the world will drive the market's growth rate

A very common condition is menstrual pain, but the need for medication and failure to function are usually less frequent. However, at least one in four women reports distressing menstrual pain marked by a need for medicine and absenteeism from research or social activities. Due to the various etiologies of the disease, the prevalence of dysmenorrhea is difficult to ascertain, with figures ranging from 45% to 95%. Thus, the surging prevalence of dysmenorrhea across globe is anticipated to drive the market.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2021 to 2028

Base Year

2020

Historic Years

2019 (Customizable to 2013 - 2018)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Drug class (Antirheumatics, TNF Alfa Inhibitors, Others), Indication (Rheumatoid Arthritis, Ankylosing Spondylitis, Chronic Plaque Psoriasis, Crohn's Disease, Ulcerative Colitis, Psoriatic Arthritis, Juvenile Idiopathic Arthritis, Hidradenitis Suppurativa, Non-Infectious Intermediate, Others), Type (Biologics, Biosimilars), Dosage Strength (40mg/0.4mlg, 80mg/0.8mlg, 20mg/0.2mlg, 10mg/0.1mlg, Others), Drug Type (Branded, Generics), Route of Administration (Oral, Parenteral, Others), Age Group (Pediatric, Adult, Geriatric), Dosage Form (Tablet, Injection, Solution, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)

Countries Covered

U.S., Canada, Mexico in North America, Germany, Sweden, Poland, Denmark, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe in Europe, Japan, China, India, South Korea, New Zealand, Vietnam, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), Brazil, Argentina, Rest of South America as a part of South America, UAE, Saudi Arabia, Oman, Qatar, Kuwait, South Africa, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA)

Market Players Covered

Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Merck & Co., Inc. (U.S.),  F. Hoffmann-La Roche Ltd. (Switzerland), Baxter (U.S.), Bayer AG (Germany), Eli Lilly and Company (U.S.), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Allergan (Ireland), AbbVie Inc. (U.S.), Abbott (U.S.), Bausch Health Companies Inc. (Canada) among others             

Data Points Covered in the Report

In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework

Segment Analysis:

Global menstrual cramp treatment market is categorized into six notable segments which are based on type, treatment type, mode of prescription, route of administration, end user and distribution channel.

  • On the basis of type, global menstrual cramp treatment market is segmented into primary dysmenorrhea and secondary dysmenorrhea. In 2021, primary dysmenorrhea segment is dominating the menstrual cramp treatment market with the market share of 56.95% as large number of patient pool suffering from primary dysmenorrhea as compared to the secondary dysmenorrhea.
  • On the basis of treatment type, global menstrual cramp treatment market is segmented into medication, therapy, surgery and others. In 2021, medication segment is dominating the menstrual cramp treatment market with the market share of 45.52% as nonsteroidal anti-inflammatory drugs and combined oral contraceptives represent first-line therapy for dysmenorrhea pain.
  • On the basis of mode of prescription, global menstrual cramp treatment market is segmented into prescription and over the counter. In 2021, over the counter segment is dominating the menstrual cramp treatment market with a market share of 54.73% due to most of the drugs being available generic and supplying pharmaceutical products without any hindrance and raising awareness among the masses by the virtues of advertising.
  • On the basis of route of administration, global menstrual cramp treatment market is segmented into oral, parenteral, implants and others. In 2021, oral segment is dominating the menstrual cramp treatment market with a market share of 47.22% because oral segment is considered the first line of treatment. Furthermore, the growing demand for various oral drug administrations serves as another driving factor.
  • On the basis of end user, global menstrual cramp treatment market is segmented into hospitals, ambulatory surgical centers, specialty centers, home healthcare and others. In 2021, hospitals segment is dominating the menstrual cramp treatment market with the market share of 43.64% because most patients are experiencing menopausal symptoms so they would be seen in the hospital to get proper diagnosis and treatment.

The hospitals segment will dominate the end user segment of the menstrual cramp treatment market

The hospitals segment will emerge as the dominating segment end user segment. This is because of the growing number of hospitals in the market especially in the developing economies. Further, growth and expansion of research development services on a global scale will further bolster the growth of this segment.

  • On the basis of distribution channel, global menstrual cramp treatment market is segmented into direct tender, retail sales, pharmacies and others. In 2021, pharmacies segment is dominating the menstrual cramp treatment market with the market share of 41.77% as variety of drugs is used in hospital pharmacies to treat menopausal disorders.

The pharmacies segment will dominate the distribution channel segment of the menstrual cramp treatment market

The pharmacies segment will emerge as the dominating segment under distribution channel. This is because of the growing number of infrastructural development activities in the market especially in the developing economies. Further, growth and expansion of the healthcare industry all around the globe will further bolster the growth of this segment.

Major Players         

Data Bridge Market Research recognizes the following companies as the market players in market: Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Merck & Co., Inc. (U.S.),  F. Hoffmann-La Roche Ltd. (Switzerland), Baxter (U.S.), Bayer AG (Germany), Eli Lilly and Company (U.S.), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Allergan (Ireland), AbbVie Inc. (U.S.), Abbott (U.S.), Bausch Health Companies Inc. (Canada).

menstrual cramp treatment market

Market Development

  • In July 2018, AbbVie received the U.S. Food and Drug Administration (FDA) approval for its drug named ORILISSA (elagolix), the first and only oral gonadotropin-releasing hormone (GnRH) antagonist for the indication of moderate to severe endometriosis pain in women.
  • In April 2019, PF Consumer Healthcare 1 LLC voluntarily recalled its ThermaCare HEATWRAPS, ADVANCED BACK PAIN THERAPY, SKU: F00573301020A, F00573301026X and F00573301009B because There is a potential for HeatWrap to include cells with a higher cell temperature than defined in lot S97473. The use of heat cell wraps with elevated temperatures presents a possible risk of injury to the skin, such as burns/blisters and/or skin irritation to the enclosed area.
  • In November 2018, Pfizer Inc. voluntarily recalled its six lots of ThermaCare HeatWrap products to the consumer level because product from the recalled lots can leak the ingredients contained in heat cell wrap.

Regional Analysis

Geographically, the countries covered in the market report are U.S., Canada, Mexico in North America, Germany, Sweden, Poland, Denmark, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe in Europe, Japan, China, India, South Korea, New Zealand, Vietnam, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), Brazil, Argentina, Rest of South America as a part of South America, UAE, Saudi Arabia, Oman, Qatar, Kuwait, South Africa, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

As per Data Bridge Market Research analysis:

North America is the dominant region in menstrual cramp treatment market during the forecast period 2021 to 2028

North America dominates the menstrual cramps treatment market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the increasing technological advancement and rising healthcare expenditure will further propel the market's growth rate in this region. Additionally, the presence of major key players and increasing medication usage will further propel the market's growth rate in this region. 

Asia-Pacific is estimated to be the fastest growing region in menstrual cramp treatment market the forecast period 2021 to 2028

Asia-Pacific is expected to be the fastest-growing region during the forecast period of 2022-2029 due to the increase in prevalence of Dysmenorrhea and menstrual health diseases for the treatment in this region. In addition, the development of healthcare infrastructure and rising government initiatives will further propel the market's growth rate in this region.    

COVID-19 Impact

A huge public health risk, COVID-19 has injured millions of individuals both physically and psychologically. The outbreak has caused many people's mental health to deteriorate, especially those who are lonely, under financial strain, socially isolated, anxious about contracting the virus, and apprehensive about the future. It has been established that stressful and uncomfortable times can harm a woman's menstrual cycle. An irregular menstrual cycle can be caused by stress, which can activate the hypothalamic-pituitary-gonadal (HPG) axis and alter the neuro-modulatory cascade that regulates GnRH. More episodes of dysmenorrhea are brought on by changes in menstrual cycles, which have a significant effect on the market.

For more detailed information about the menstrual cramp treatment market, visit: https://www.databridgemarketresearch.com/reports/global-menstrual-cramps-treatment-market